secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-02-03T23:59:59+00:00
Accession:  0001999371-26-002429
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix prelim 2025: net loss $118.9M vs $130.0M; cash $207.6M funds ops into Q1 2027
--------------------------------------------------------------------------------

- Cash & equivalents $207.6M at Dec 31, 2025; 12.79M shares outstanding as of Jan 30, 2026.
- Net loss $118.9M (2025) vs $130.0M (2024); net cash used in operations $99.0M vs $60.9M.
- Net product revenue $13.1M (2025) vs $10.1M (2024); Zembrace/Tosymra $11.7M vs $10.1M.
- TONMYA launch Nov 17, 2025 generated $1.4M from launch to Dec 31, 2025.
- Capital expenditures $3.4M in 2025 vs $0.1M in 2024; cash expected to fund ops into Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126002429/0001999371-26-002429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126002429/tonix-8k_020326.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-002429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer